Highlights from the past 3
months include:
- Rewarding harvest of
industrial hemp in Carson City, Nevada
Purchased $1mm worth of processing equipment fully in cash (without
financing)
Acquired Pharmaceutical Development Corp LTD in Lesotho,
South Africa
Shipped our first set of samples to Switzerland and began marketing
in the European market
Created Joint Venture with ChampRX
With top leading industry
experts on their agricultural team and advanced seed genetics,
Corix had a banner late harvest in Carson City, Nevada to close out
2017. Corix was able to excel in both quality and quantity in the
cultivation of industrial hemp. The rewarding harvest not only
proved their capabilities in cultivation, but the substantial
inventory also became a promising start for 2018.
Corix has also scaled their
manufacturing divisions with major equipment purchases and
upgrades. Corix has obtained over $1mm worth of proprietary and
agricultural equipment, all paid in full and without financing.
These upgrades include a new trimming line, a new packaging line,
stripping equipment, drying and preservation systems,
post-processing equipment for CBD isolate, and Genius extraction
equipment. Machinery of this scale paired up with their strong raw
inventory, Corix has increased their overall capacity, will allow
them to complete demands they could not fulfill in the past, and
facilitate the continuous new incoming orders.
In terms of international
sales, Corix Bioscience spent the last three months of 2017 paving
way for the global market. By acquiring Pharmaceutical
Development Corp LTD in South Africa, Corix has attained the
first license issued by the Government of Lesotho that enables them
to import and the export cannabis and cannabis resin in various
forms. Corix also has an export license that allows them to export
cannabis and CBD products to approximately 30 plus different
countries in the EU, Canada, Australia, Mexico, Brazil and New
Zealand. In the past quarter, Corix also shipped out their first
sample order to Switzerland, as a first step into the European
market.
Corix also solidified their
joint venture with ChampRX for its products. Corix will be their
official CBD manufacturer and a 25% equity holder in ChampRX. Both
companies will be ring sponsors for Shannon Briggs's next title
fight. Corix will also have access to the marketing for ChampRX and
its partners. Under the terms of the agreement, Corix will provide
the science and manufacturing behind the products and ChampRX will
market and promote the product.
ChampRX is composed of
several current and former boxers. This includes many title holders
including 2X Heavyweight Champion Shannon Briggs, 2X Heavyweight
Champion Chris Byrd with several other Olympic and Boxing Champions
including Lamon Brewster, Montell Griffin and Ray Mercer, each
multiple boxing champion. For more information visit their website
at ChampRXCBD.com.
Corix has had a promising
fourth quarter with strong synergies carrying into 2018. Corix is
more than well-prepared for the new year and is well on their way
to achieve their ultimate goals.
About Corix
Bioscience Inc;
Corix Bioscience, Inc.
(“Corix”) is a fully reporting Wyoming corporation listed as
OTCQB:CXBS. Corix is the developer of proprietary cannabis
and industrial hemp strains using tissue cell cultures to propagate
living plants, with plans to patent the strains to be used in the
pharmaceutical medical industries.
Our methods allow us to
create and breed new and existing plant strains from tissue cells
free of any pathogens or disease. We grow these plants to maturity
and extract the oils which are the “medicine” part of the plant.
Our sales are focused towards the medical industry and we are
developing brand named products to be released in early
2018.
Company headquarters are in
Phoenix, AZ and with our laboratory and processing facility in
Carson City, NV and we grow in Genoa, NV. We are currently looking
at expanding our footprint into Washington, Oregon, California and
Arizona. The Company’s mission is to create clean and consistent
products in medical grade facilities. Consistency being the
key which will ultima yield a safer and superior product, better
for people and the environment. For more information, please visit
Corix’s website at www.corixbioscience.com
Forward Looking
Statement
This press release, and
those statements regarding Corix Bioscience and the Company,
contain forward-looking statements that relate to expectations,
beliefs, projections, future plans and strategies, anticipated
events and similar expressions. Forward-looking statements
may be identified by use of words such as "may," "will," "should,"
"expects," "intends," "plans," "anticipates," "believes,"
"estimates," or "potential" or similar words or phrases which are
predictions of or indicate future events or trends.
Statements such as those concerning potential acquisition activity,
investment objectives, strategies, opportunities, other plans and
objectives for future operations or economic performance are based
on the Company's current expectations, plans, estimates,
assumptions and beliefs that involve numerous risks and
uncertainties. You are cautioned not to place undue reliance
on any forward-looking statements and the Company disclaims any
obligation to publicly update or revise any forward-looking
statement to reflect changes in underlying assumptions or factors,
new information, future events or other changes. Please refer
to Company's filings with the Securities and Exchange Commission
for further information.
SOURCE Corix Bioscience
Inc.
Related
Links
http://www.corixbioscience.com
